Dyne Therapeutics (NASDAQ:DYN) Insider Douglas Kerr Sells 1,564 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Douglas Kerr sold 1,564 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $18.36, for a total transaction of $28,715.04. Following the sale, the insider owned 170,042 shares in the company, valued at $3,121,971.12. The trade was a 0.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $18.28 on Friday. Dyne Therapeutics, Inc. has a 1-year low of $8.06 and a 1-year high of $25.00. The company has a current ratio of 19.92, a quick ratio of 22.25 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $3.02 billion, a PE ratio of -5.68 and a beta of 1.08. The firm’s 50 day simple moving average is $18.30 and its 200 day simple moving average is $18.64.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same quarter in the previous year, the firm earned ($1.05) earnings per share. As a group, analysts expect that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $50 price target, while lifting several earnings forecasts for Dyne Therapeutics, signaling continued analyst confidence in the stock’s longer-term potential.
• Positive Sentiment: Lifesci Capital also increased its earnings estimates for 2026 and 2026 quarterly periods, reflecting improved expectations for Dyne Therapeutics’ financial outlook.
• Neutral Sentiment: Dyne Therapeutics said management will participate in upcoming investor conferences, which can help keep the company visible to shareholders but does not change the fundamentals by itself. Dyne Therapeutics to Participate in Upcoming Investor Conferences
• Neutral Sentiment: The company received an average brokerage rating of Moderate Buy, suggesting Wall Street sentiment remains constructive overall. Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Moderate Buy” by Brokerages
• Negative Sentiment: CEO John Cox, CFO Erick Lucera, and insider Douglas Kerr each sold small blocks of stock, which can weigh on sentiment, although the filings say the sales were made to cover tax obligations tied to equity vesting.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Wall Street Zen lowered Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 2nd. Chardan Capital restated a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. Finally, JPMorgan Chase & Co. decreased their target price on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 20th. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.21.

Institutional Trading of Dyne Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. raised its position in shares of Dyne Therapeutics by 523.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after buying an additional 14,727,667 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Dyne Therapeutics by 14.9% during the 4th quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock valued at $219,376,000 after buying an additional 1,455,151 shares in the last quarter. State Street Corp raised its position in shares of Dyne Therapeutics by 27.0% during the 4th quarter. State Street Corp now owns 6,692,745 shares of the company’s stock valued at $130,910,000 after buying an additional 1,423,828 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in shares of Dyne Therapeutics by 45.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock valued at $101,164,000 after buying an additional 1,618,000 shares in the last quarter. Finally, Orbis Allan Gray Ltd purchased a new stake in shares of Dyne Therapeutics during the 4th quarter valued at $93,926,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.